Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
News or no News, named partners or not, this share price is not for moving.... I guess the company will have to show good figures in its financials before the world wakes up, responds etc.
Almost alone. A good outcome with Hikma, but we wont know for a while how significant this is in monetary terms.
It's all good news. Heading in the right direction. A top 5 pharma paying upfront with the right to license is great. Built in (but not guaranteed) value route. The Inbrx news was good too, back in May.
The future product might then have a similar use to that being developed by Poolbeg (who bought the technology from Uni of Warwick). Theirs is derived from influenza virus but basically stimulates a strong interferon release, which then helps reduce the impact of any respiratory virus.
Good spot! I had thought about generic lifescience supplier like ThermoFisher who wanted to be able to supply easier to use consumables, but that match looks very accurate.
Hi Jones1961,
This may now be redundant , but just in case.
The information (now released as an RNS) was in the public domain. The news is that GSK tried to fight an Arecor patent and Arecor won. Whether that translates to GSK or someone else asking for a license is of course entirely another matter.
Great news about the patent being upheld. Even better news is that GSK cared enough about the patent to try and invalidate it. Good evidence that it's something GSK cares about it!
Are all the price monitoring extensions simply because the spread is so big?
Andrea
I expect it will be quite a jolly occasion tomorrow when they announce the half year result (given the share movement).
It may have higher attendance than might otherwise have been the case and I think there will be a few further potential buyers once they have had a good presentation to look at.
Thanks
By the way what does code 1 and 0 mean?
To be honest this company doesn't need a new RNS to be valued much more highly than it is right now. I imagine that this week's activity has alerted a few folk to it and the lack of liquidity has meant the price responds very quickly. But people who didn't know about it went and read up and saw that the most recent deal for rapid acting insulin was ~£500m and Novo bought a Bristol based start-up for £800m . And that's just one part of Arecor's diabetes technology, let alone the other bits.
The spread is now 11% and there's virtually no liquidity. It's not going to move much until there's some new news.
£100m and still vastly undervalued. Not sure which part of the business will be bigger, the insulin and diabetes activities or all the other drugs that need injection and are better if you can just have them as a concentrated liquid (i.e. a smaller injection) stored at room temperature .
Now the insulin side has all been tested in animals and it has translated beautifully to humans, but the other part of the business has already been accumulating licenses with very handsome royalty rates and or license fees.
In typical Arecor fashion, the results of the latest trials are exactly as predicted. I'll be interested to see the curves when they are published - faster than NovoRapid, yet 5 times more concentrated.
Yep, the licenses are starting to pile up for drugs that are known to work, but are just very inconvenient. Nobody will choose an inconvenient drug when there's a handy one available.
Apologies if it's been posted, please could anyone direct me. I went to see if COVIDITY showed up in clinicaltrials.gov in the hope that the needle free injection would be disclosed, but couldnt find Covidity (only 2 Scancell trials listed).
1) does anyone know if it has been listed and if so what the number is?
2) has the needle free nature been disclosed while I was looking the other way?